Publikation:

Optimizing drug discovery by Investigative Toxicology : Current and future trends

Lade...
Vorschaubild

Dateien

Beilmann_2-buzlrcalpi8x1.pdf
Beilmann_2-buzlrcalpi8x1.pdfGröße: 2.94 MBDownloads: 658

Datum

2019

Autor:innen

Beilmann, Mario
Boonen, Harrie
Czich, Andreas
Dear, Gordon
Hewitt, Philip
Steger-Hartmann, Thomas
et al.

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

ArXiv-ID

Internationale Patentnummer

Link zur Lizenz

Angaben zur Forschungsförderung

European Union (EU): 681002

Projekt

EUToxRisk21
Open Access-Veröffentlichung
Open Access Gold
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Alternatives to Animal Experimentation : ALTEX. 2019, 36(2), pp. 289-313. ISSN 1868-596X. eISSN 1868-8551. Available under: doi: 10.14573/altex.1808181

Zusammenfassung

Investigative Toxicology describes the de-risking and mechanistic elucidation of toxicities, supporting early safety decisions in the pharmaceutical industry. Recently, Investigative Toxicology has contributed to a shift in pharmaceutical toxicology, from a descriptive to an evidence-based, mechanistic discipline. This was triggered by high costs and low throughput of Good Laboratory Practice in vivo studies, and increasing demands for adhering to the 3R (Replacement, Reduction and Refinement) principles of animal welfare. Outside the boundaries of regulatory toxicology, Investigative Toxicology has the flexibility to embrace new technologies, enhancing translational steps from in silico, in vitro to in vivo mechanistic understanding to eventually predict human response. One major goal of Investigative Toxicology is improving preclinical decisions, which coincides with the concept of animal-free safety testing. Currently, compounds under preclinical development are being discarded due to the use of inappropriate animal models. Progress in Investigative Toxicology could lead to humanized in vitro test systems and the development of medicines less reliant on animal tests. To advance this field a group of 14 European-based leaders from the pharmaceutical industry founded the Investigative Toxicology Leaders Forum (ITLF), an open, non-exclusive and pre-competitive group that shares knowledge and experience. The ITLF collaborated with the Centre for Alternatives to Animal Testing Europe (CAAT-Europe) to organize an "Investigative Toxicology Think-Tank", which aimed to enhance the interaction with experts from academia and regulatory bodies in the field. Summarizing the topics and discussion of the workshop, this article highlights Investigative Toxicology's position by identifying key challenges and perspectives.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690BEILMANN, Mario, Harrie BOONEN, Andreas CZICH, Gordon DEAR, Philip HEWITT, Mardas DANESHIAN, Thomas HARTUNG, Marcel LEIST, Costanza ROVIDA, Thomas STEGER-HARTMANN, 2019. Optimizing drug discovery by Investigative Toxicology : Current and future trends. In: Alternatives to Animal Experimentation : ALTEX. 2019, 36(2), pp. 289-313. ISSN 1868-596X. eISSN 1868-8551. Available under: doi: 10.14573/altex.1808181
BibTex
@article{Beilmann2019Optim-44428,
  year={2019},
  doi={10.14573/altex.1808181},
  title={Optimizing drug discovery by Investigative Toxicology : Current and future trends},
  number={2},
  volume={36},
  issn={1868-596X},
  journal={Alternatives to Animal Experimentation : ALTEX},
  pages={289--313},
  author={Beilmann, Mario and Boonen, Harrie and Czich, Andreas and Dear, Gordon and Hewitt, Philip and Daneshian, Mardas and Hartung, Thomas and Leist, Marcel and Rovida, Costanza and Steger-Hartmann, Thomas}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/44428">
    <dc:language>eng</dc:language>
    <dc:creator>Boonen, Harrie</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-01-07T14:42:10Z</dc:date>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/44428/1/Beilmann_2-buzlrcalpi8x1.pdf"/>
    <dc:contributor>Czich, Andreas</dc:contributor>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/44428/1/Beilmann_2-buzlrcalpi8x1.pdf"/>
    <dc:creator>Dear, Gordon</dc:creator>
    <dcterms:abstract xml:lang="eng">Investigative Toxicology describes the de-risking and mechanistic elucidation of toxicities, supporting early safety decisions in the pharmaceutical industry. Recently, Investigative Toxicology has contributed to a shift in pharmaceutical toxicology, from a descriptive to an evidence-based, mechanistic discipline. This was triggered by high costs and low throughput of Good Laboratory Practice in vivo studies, and increasing demands for adhering to the 3R (Replacement, Reduction and Refinement) principles of animal welfare. Outside the boundaries of regulatory toxicology, Investigative Toxicology has the flexibility to embrace new technologies, enhancing translational steps from in silico, in vitro to in vivo mechanistic understanding to eventually predict human response. One major goal of Investigative Toxicology is improving preclinical decisions, which coincides with the concept of animal-free safety testing. Currently, compounds under preclinical development are being discarded due to the use of inappropriate animal models. Progress in Investigative Toxicology could lead to humanized in vitro test systems and the development of medicines less reliant on animal tests. To advance this field a group of 14 European-based leaders from the pharmaceutical industry founded the Investigative Toxicology Leaders Forum (ITLF), an open, non-exclusive and pre-competitive group that shares knowledge and experience. The ITLF collaborated with the Centre for Alternatives to Animal Testing Europe (CAAT-Europe) to organize an "Investigative Toxicology Think-Tank", which aimed to enhance the interaction with experts from academia and regulatory bodies in the field. Summarizing the topics and discussion of the workshop, this article highlights Investigative Toxicology's position by identifying key challenges and perspectives.</dcterms:abstract>
    <dc:contributor>Boonen, Harrie</dc:contributor>
    <dc:creator>Beilmann, Mario</dc:creator>
    <dc:contributor>Beilmann, Mario</dc:contributor>
    <dc:contributor>Steger-Hartmann, Thomas</dc:contributor>
    <dc:creator>Hartung, Thomas</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:rights>Attribution 4.0 International</dc:rights>
    <dc:contributor>Rovida, Costanza</dc:contributor>
    <dcterms:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/"/>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-01-07T14:42:10Z</dcterms:available>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Daneshian, Mardas</dc:creator>
    <dc:creator>Hewitt, Philip</dc:creator>
    <dc:contributor>Dear, Gordon</dc:contributor>
    <dcterms:issued>2019</dcterms:issued>
    <dc:creator>Leist, Marcel</dc:creator>
    <dcterms:title>Optimizing drug discovery by Investigative Toxicology : Current and future trends</dcterms:title>
    <dc:creator>Czich, Andreas</dc:creator>
    <dc:contributor>Hartung, Thomas</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/44428"/>
    <dc:contributor>Leist, Marcel</dc:contributor>
    <dc:contributor>Hewitt, Philip</dc:contributor>
    <dc:creator>Steger-Hartmann, Thomas</dc:creator>
    <dc:creator>Rovida, Costanza</dc:creator>
    <dc:contributor>Daneshian, Mardas</dc:contributor>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen